David King, Ph.D., is co-founder and CSO of Lassen. David is an internationally recognized expert in the discovery and development of antibody therapeutics and an experienced executive leader in the biotech industry. Prior to joining Lassen, David served as the CSO of aTyr Pharma, developing novel therapeutics based on tRNA synthetase biology, and CSO of AnaptysBio, developing antibody-based therapeutics in autoimmune diseases and oncology. David also worked at Medarex (acquired by BMS) designing and developing antibody therapeutics for oncology and autoimmune diseases and was part of the team that developed innovative therapies, including OPDIVO®, the first approved anti-PD1 therapeutic. Earlier in his career, David worked at Celltech (acquired by UCB pharma) where he contributed to the development of a number of fundamental antibody technologies and the design and development of the approved antibodies CIMZIA® and MYLOTARG®. David received his Ph.D. in Biochemistry from the University of Surrey and a B.Sc. in Biochemistry from the University of Warwick.